Clinical Trial Update: Evaluation of MK-1075 in Participants With Hepatitis C Virus (HCV) Infection (MK-1075-002) [Phase 1]

View source ↗

Summary

This publication reports results from a Phase 1 study evaluating MK-1075 in participants with hepatitis C virus infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• MK-1075

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C | Phase 1 | Status: COMPLETED | Results posted: 2018-12-31